Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure

Completed · Not applicable

Conditions studied: Multiple Myeloma

In brief

The purpose of this investigation is to establish that hematopoetic stem cells collected on a new centrifugal blood separator, CaridianBCT's Spectra Optia Apheresis System, are able to reconstitute the hematopoetic systems of patients treated with myeloablative therapy, equivalent to hematopoetic cells harvested on the predicate COBE® Spectra platform.

Key facts

Study ID

NCT01292486

Run by

Terumo BCT

People needed

32

Starts

2011-02-01

Expected to finish

2011-12-01

Last updated by the study team

2013-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic confirmation of Multiple Myeloma
• Patients intended to be treated with myeloablative therapy and autologous hematopoetic stem-cell transplant within one month of stem-cell collection
• Patients whose stem-cell mobilization regimen includes G-CSF (granulocyte-colony stimulating factor)
• Males or non-pregnant females, who are 18 years of age or older
• Karnofsky score of ≥70%

You may not qualify if…

• Patients with pre-mobilization platelet count < 75,000/µL
• Patients who have received pelvic bone marrow irradiation as part of their conditioning therapy
• Patients who have had a previous hematopoetic stem-cell transplant
• Patients who have had a previous hematopoetic stem-cell collection failure
• Impaired cardiac function, as evidenced by left ventricular ejection fraction <40%.
• Impaired hepatic function, as evidenced by alanine transaminase >2.5 x normal
• Impaired pulmonary function as evidenced by diffusion capacity of the lung for carbon monoxide (adjusted for patient hematocrit, if indicated) or forced expiratory volume in 1 second <50% of predicted
• Impaired renal function, as evidenced by a creatinine clearance < 40 mL/min
• Impaired coagulation, as evidenced by a prothrombin time (PT) > twice normal
• Pregnancy or lactation
• Seropositivity for Human Immunodeficiency Virus-1/2, Hepatitis B Virus, or Hepatitis C Virus
• Documented bacterial or fungal infection that requires intravenous antibiotics to be started or continued while undergoing apheresis collection on the Spectra Optia device
• Subjects enrolled in study protocols that could affect number of CD34+ cells (pluripoten hematopoetic stem stells) collected or kinetics of neutrophil recovery
• Altered mental status, as evidenced by the inability to provide effective informed consent

Where it is running

• Emory University — Atlanta, Georgia, United States
• Indiana University — Indianapolis, Indiana, United States
• Duke University Medical Center — Durham, North Carolina, United States
• University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.